PCN115 COST UTILITY ANALYSIS OF 90Y-IBRITUMOMAB TIUXETAN FOLLOWING FIRST-LINE CHEMOTHERAPY COMPARED TO NO FOLLOW-UP IN PATIENTS WITH STAGE III OR IV FOLLICULAR LYMPHOMA IN SPAIN

SG Eggington; C Piñol; E Musi; A Valderrama

doi:10.1016/s1098-3015(10)74366-7

PCN115 COST UTILITY ANALYSIS OF 90Y-IBRITUMOMAB TIUXETAN FOLLOWING FIRST-LINE CHEMOTHERAPY COMPARED TO NO FOLLOW-UP IN PATIENTS WITH STAGE III OR IV FOLLICULAR LYMPHOMA IN SPAIN

Value in Health ◽

10.1016/s1098-3015(10)74366-7 ◽

2009 ◽

Vol 12 (7) ◽

pp. A279

Author(s):

SG Eggington ◽

C Piñol ◽

E Musi ◽

A Valderrama

Keyword(s):

Follicular Lymphoma ◽

Cost Utility ◽

Cost Utility Analysis ◽

Stage Iii ◽

Utility Analysis ◽

First Line ◽

Ibritumomab Tiuxetan ◽

Line Chemotherapy

Download Full-text

Cost-Utility Analysis of Continuation Versus Discontinuation of First-Line Chemotherapy in Patients With Metastatic Squamous-Cell Esophageal Cancer: Economic Evaluation Alongside the E-DIS Trial

Value in Health ◽

10.1016/j.jval.2020.11.017 ◽

2021 ◽

Vol 24 (5) ◽

pp. 676-682 ◽

Cited By ~ 1

Author(s):

Sophie Marguet ◽

Antoine Adenis ◽

Stéphanie Delaine-Clisant ◽

Nicolas Penel ◽

Julia Bonastre

Keyword(s):

Esophageal Cancer ◽

Economic Evaluation ◽

Squamous Cell ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

First Line ◽

Squamous Cell Esophageal Cancer ◽

Line Chemotherapy

Download Full-text

3612 POSTER Cost Utility Analysis of Modified FLOX as First Line Chemotherapy for Metastatic Colorectal Cancer

European Journal of Cancer ◽

10.1016/s0959-8049(11)71209-6 ◽

2011 ◽

Vol 47 ◽

pp. S262

Author(s):

M.P. Mak ◽

F.H. Souza ◽

D.R. Nebuloni ◽

D.F. Saragiotto ◽

G. Castro ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

First Line ◽

Line Chemotherapy

Download Full-text

PCN36 A COST UTILITY ANALYSIS OF FIRST-LINE CHEMOTHERAPY REGIMENS IN THE TREATMENT OF METASTATIC BREAST CANCERAFTERANTHRACYCLINE FAILURE

Value in Health ◽

10.1016/s1098-3015(10)67274-9 ◽

2005 ◽

Vol 8 (6) ◽

pp. A44 ◽

Cited By ~ 1

Author(s):

K Le Lay ◽

L Riou França ◽

S Avoinet ◽

N Chemali ◽

R Launois

Keyword(s):

Metastatic Breast ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

First Line ◽

Line Chemotherapy

Download Full-text

A Cost-Utility Analysis Comparing Two Sequences of Treatment for First-Line Chemotherapy in Metastatic Prostate Cancer (MCRPC): Cabazitaxel Followed by Docetaxel Versus Docetaxel Followed by Cabazitaxel

Value in Health ◽

10.1016/j.jval.2017.08.262 ◽

2017 ◽

Vol 20 (9) ◽

pp. A444 ◽

Cited By ~ 1

Author(s):

M Schwager ◽

K Fizazi ◽

N Zaghdoud ◽

R Delva ◽

G Gravis Mescam ◽

...

Keyword(s):

Prostate Cancer ◽

Metastatic Prostate Cancer ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

First Line ◽

Line Chemotherapy

Download Full-text

Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost–utility analysis

Annals of Oncology ◽

10.1093/annonc/mdq431 ◽

2011 ◽

Vol 22 (3) ◽

pp. 567-574 ◽

Cited By ~ 12

Author(s):

M. Joerger ◽

K. Matter-Walstra ◽

M. Früh ◽

U. Kühnel ◽

T. Szucs ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Small Cell Lung ◽

First Line ◽

Line Chemotherapy

Download Full-text

Modified FLOX as first-line chemotherapy for metastatic colorectal cancer patients in the public health system in Brazil: Effectiveness and cost-utility analysis

Molecular and Clinical Oncology ◽

10.3892/mco.2012.12 ◽

2012 ◽

Vol 1 (1) ◽

pp. 175-179 ◽

Cited By ~ 9

Author(s):

DANIELA R. NEBULONI ◽

MILENA P. MAK ◽

FABIANO HAHN SOUZA ◽

DANIEL F. SARAGIOTTO ◽

THIAGO JÚLIO ◽

...

Keyword(s):

Public Health ◽

Colorectal Cancer ◽

Public Health System ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

First Line ◽

The Public ◽

Colorectal Cancer Patients ◽

Line Chemotherapy

Download Full-text

O-062 Economic assessment of first-line chemotherapy in symptomaticadvanced stage NSCLC in Belgium: A cost-utility analysis (CUA)

Lung Cancer ◽

10.1016/s0169-5002(05)80194-1 ◽

2005 ◽

Vol 49 ◽

pp. S24

Author(s):

C. Dooms ◽

Y. Lievens ◽

J. Vansteenkiste

Keyword(s):

Economic Assessment ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

First Line ◽

Line Chemotherapy

Download Full-text

PCN11 COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS AFTER FIRST-LINE FAILURE OF IMATINIB IN CHRONIC MYELOID LEUKEMIA (CML) IN AUSTRIA

Value in Health ◽

10.1016/s1098-3015(10)65169-8 ◽

2007 ◽

Vol 10 (6) ◽

pp. A325 ◽

Cited By ~ 2

Author(s):

JFS Logman ◽

MJ Taylor ◽

K Neumann ◽

L Kutikova ◽

KH Cerri ◽

...

Keyword(s):

Chronic Myeloid Leukemia ◽

Myeloid Leukemia ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

First Line

Download Full-text

Cost-utility Analysis of Primary Open-angle Glaucoma according to Follow-up Observation Period

Journal of the Korean Ophthalmological Society ◽

10.3341/jkos.2018.59.9.842 ◽

2018 ◽

Vol 59 (9) ◽

pp. 842

Author(s):

Jin A Choi ◽

Jin Woo Kwon ◽

Donghyun Jee

Keyword(s):

Primary Open Angle Glaucoma ◽

Open Angle Glaucoma ◽

Cost Utility ◽

Cost Utility Analysis ◽

Open Angle ◽

Utility Analysis ◽

Observation Period

Download Full-text

PCN248 COST-UTILITY ANALYSIS OF FIRST-LINE THERAPY FOR ADVANCED AND METASTATIC PANCREATIC CANCER IN JAPAN.

Value in Health ◽

10.1016/j.jval.2019.09.443 ◽

2019 ◽

Vol 22 ◽

pp. S484

Author(s):

Y. Takumoto ◽

T. Kudo ◽

H. Narimatsu ◽

Y. Sasahara ◽

T. Murata ◽

...

Keyword(s):

Pancreatic Cancer ◽

Cost Utility ◽

Cost Utility Analysis ◽

Metastatic Pancreatic Cancer ◽

Utility Analysis ◽

First Line ◽

First Line Therapy ◽

Line Therapy

Download Full-text